The FDA has granted Breakthrough Therapy Designation to Opdivo, a drug from New York City-based drug developer Bristol-Myers Squibb that potentially treats bladder cancer.
The FDA's Breakthrough Therapy Designation is intended to expedite the development and review of drugs that show early signs of potential clinical benefit in serious diseases to provide patients with access to new therapies as soon as possible.
Bristol-Myers Squibb shared results from a Phase 2 study as well as other supportive data surrounding Opdivo in its request for the designation.
The company hopes to file a market application for the drug in several months, according to Jean Viallet, MD, global clinical research lead of oncology at Bristol-Myers Squibb.
The FDA previously granted Breakthrough Therapy Designations of Opdivo for a variety of indications, including previously treated melanoma and non-squamous, non-small cell lung cancer.
More articles on supply chain:
Natco Pharma earns FDA approval for ulcer drug
How Britain's exit from the EU will affect the drug market
Allergy drug launch postponed after failed dosage study